Egalet Corp Company Profile (NASDAQ:EGLT)

About Egalet Corp (NASDAQ:EGLT)

Egalet Corp logoEgalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EGLT
  • CUSIP: N/A
  • Web: www.egalet.com
Capitalization:
  • Market Cap: $70.1 million
  • Outstanding Shares: 25,034,000
Average Prices:
  • 50 Day Moving Avg: $3.68
  • 200 Day Moving Avg: $5.50
  • 52 Week Range: $2.62 - $10.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.31
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $19.73 million
  • Price / Sales: 3.55
  • Book Value: ($0.69) per share
  • Price / Book: -4.06
Profitability:
  • EBIDTA: ($79,930,000.00)
  • Net Margins: -251.79%
  • Return on Equity: -127.84%
  • Return on Assets: -51.10%
Debt:
  • Debt-to-Equity Ratio: 3.21%
  • Current Ratio: 4.36%
  • Quick Ratio: 4.30%
Misc:
  • Average Volume: 298,508 shs.
  • Beta: 0.55
  • Short Ratio: 24.68
 

Frequently Asked Questions for Egalet Corp (NASDAQ:EGLT)

What is Egalet Corp's stock symbol?

Egalet Corp trades on the NASDAQ under the ticker symbol "EGLT."

How were Egalet Corp's earnings last quarter?

Egalet Corp (NASDAQ:EGLT) posted its quarterly earnings results on Wednesday, May, 10th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.90) by $0.12. The business earned $5.57 million during the quarter, compared to the consensus estimate of $6.92 million. Egalet Corp had a negative net margin of 251.79% and a negative return on equity of 127.84%. During the same quarter in the prior year, the firm posted ($0.76) EPS. View Egalet Corp's Earnings History.

Where is Egalet Corp's stock going? Where will Egalet Corp's stock price be in 2017?

4 equities research analysts have issued 12-month price objectives for Egalet Corp's shares. Their predictions range from $8.00 to $24.00. On average, they expect Egalet Corp's share price to reach $14.13 in the next year. View Analyst Ratings for Egalet Corp.

What are analysts saying about Egalet Corp stock?

Here are some recent quotes from research analysts about Egalet Corp stock:

  • 1. According to Zacks Investment Research, "Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in the developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications. Its principal product candidate consist of Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe pain and Egalet-003 which are in pre-clinical trials. Egalet Corporation is based in City of Westminster, United Kingdom. " (5/10/2017)
  • 2. Cantor Fitzgerald analysts commented, "We maintain our Overweight rating but lower our PT to $13/ share (from $15) following 4Q16 and YE16 results and the delay of clinical progress for Egalet-002 which is now expected to file an NDA in 2019 vs. previous guidance of mid-2017. We believe that investors will be focused on the imminent launch of Arymo, expected later this month and the continued growth of Sprix and Oxaydo. We believe that the restructuring of the sales force which includes an exclusive Sprix sales team and in-house positioning as well as inducement grants will provide a new source of motivation." (3/11/2017)

Who are some of Egalet Corp's key competitors?

Who owns Egalet Corp stock?

Egalet Corp's stock is owned by a number of of retail and institutional investors. Top institutional investors include Omega Fund Management LLC (11.73%), FMR LLC (11.33%), Vanguard Group Inc. (2.63%), HighTower Advisors LLC (1.05%), Geode Capital Management LLC (0.47%) and New Jersey Better Educational Savings Trust (0.41%). Company insiders that own Egalet Corp stock include Deanne F Melloy, Jeffrey M Dayno, Mark Strobeck, Patrick M Shea, Paul Varki, Robert S Radie and Stan Musial. View Institutional Ownership Trends for Egalet Corp.

Who sold Egalet Corp stock? Who is selling Egalet Corp stock?

Egalet Corp's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Sheaff Brock Investment Advisors LLC, Morgan Stanley, Bank of New York Mellon Corp, Janney Montgomery Scott LLC, Raymond James Financial Services Advisors Inc., TIAA CREF Investment Management LLC and Goldman Sachs Group Inc.. Company insiders that have sold Egalet Corp stock in the last year include Jeffrey M Dayno, Mark Strobeck, Patrick M Shea, Paul Varki, Robert S Radie and Stan Musial. View Insider Buying and Selling for Egalet Corp.

Who bought Egalet Corp stock? Who is buying Egalet Corp stock?

Egalet Corp's stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., New Jersey Better Educational Savings Trust, KCG Holdings Inc., SG Americas Securities LLC, HighTower Advisors LLC and Geode Capital Management LLC. View Insider Buying and Selling for Egalet Corp.

How do I buy Egalet Corp stock?

Shares of Egalet Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Egalet Corp stock cost?

One share of Egalet Corp stock can currently be purchased for approximately $2.80.

Analyst Ratings

Consensus Ratings for Egalet Corp (NASDAQ:EGLT) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.13 (404.46% upside)

Analysts' Ratings History for Egalet Corp (NASDAQ:EGLT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/13/2017Cantor FitzgeraldSet Price TargetBuy$13.00 -> $8.00HighView Rating Details
5/12/2017GabelliUpgradeHold -> Buy$9.50HighView Rating Details
3/11/2017GuggenheimReiterated RatingBuy$24.00N/AView Rating Details
1/11/2017JMP SecuritiesReiterated RatingOutperform$15.00N/AView Rating Details
3/14/2016Janney Montgomery ScottInitiated CoverageNeutral$8.00N/AView Rating Details
8/7/2015Canaccord GenuityReiterated RatingBuyN/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Egalet Corp (NASDAQ:EGLT)
Earnings by Quarter for Egalet Corp (NASDAQ:EGLT)
Earnings History by Quarter for Egalet Corp (NASDAQ:EGLT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.90)($1.02)$6.92 million$5.57 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.92)($0.87)$5.37 million$6.14 millionViewListenView Earnings Details
11/4/2016Q316($0.90)($1.10)$4.50 million$4.70 millionViewN/AView Earnings Details
8/4/2016Q216($0.82)($0.97)$3.83 million$3.45 millionViewN/AView Earnings Details
5/10/2016Q116($0.87)($0.76)$3.50 million$2.70 millionViewListenView Earnings Details
3/8/2016Q415($0.91)($0.28)$2.80 million$2.10 millionViewN/AView Earnings Details
11/4/2015Q315($0.90)($0.81)$1.62 million$1.30 millionViewN/AView Earnings Details
8/6/2015Q215($1.02)($0.98)$0.95 million$0.96 millionViewN/AView Earnings Details
5/7/2015Q1 2015($0.98)($1.02)$3.00 million$0.81 millionViewN/AView Earnings Details
3/16/2015Q414($0.71)($0.52)$0.30 million$0.83 millionViewN/AView Earnings Details
11/12/2014Q314($0.75)($0.63)$0.35 millionViewN/AView Earnings Details
8/12/2014Q214($0.41)($0.73)$0.49 millionViewN/AView Earnings Details
5/13/2014Q114($0.16)($1.34)$0.26 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Egalet Corp (NASDAQ:EGLT)
Current Year EPS Consensus Estimate: $-3.50 EPS
Next Year EPS Consensus Estimate: $-2.14 EPS

Dividends

Dividend History for Egalet Corp (NASDAQ:EGLT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Egalet Corp (NASDAQ:EGLT)
Insider Ownership Percentage: 13.20%
Institutional Ownership Percentage: 69.79%
Insider Trades by Quarter for Egalet Corp (NASDAQ:EGLT)
Institutional Ownership by Quarter for Egalet Corp (NASDAQ:EGLT)
Insider Trades by Quarter for Egalet Corp (NASDAQ:EGLT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/3/2017Paul VarkiSVPSell806$5.05$4,070.30View SEC Filing  
4/3/2017Stan MusialCFOSell8,613$5.04$43,409.52View SEC Filing  
3/31/2017Jeffrey M DaynoInsiderSell536$5.16$2,765.76View SEC Filing  
3/31/2017Mark StrobeckCOOSell8,700$5.11$44,457.00View SEC Filing  
3/20/2017Patrick M SheaInsiderSell4,250$4.75$20,187.50View SEC Filing  
1/3/2017Jeffrey M DaynoInsiderSell536$7.75$4,154.00View SEC Filing  
1/3/2017Paul VarkiSVPSell806$7.75$6,246.50View SEC Filing  
1/3/2017Stan MusialCFOSell13,480$7.73$104,200.40View SEC Filing  
12/30/2016Mark StrobeckCOOSell8,700$7.81$67,947.00View SEC Filing  
10/3/2016Paul VarkiSVPSell806$7.56$6,093.36View SEC Filing  
10/3/2016Robert S RadieInsiderSell15,000$7.47$112,050.00View SEC Filing  
10/3/2016Stan MusialCFOSell13,480$7.47$100,695.60View SEC Filing  
9/30/2016Jeffrey M DaynoInsiderSell536$7.69$4,121.84View SEC Filing  
9/30/2016Mark StrobeckCOOSell33,700$7.58$255,446.00View SEC Filing  
7/6/2016Robert S RadieCEOSell15,000$5.01$75,150.00View SEC Filing  
7/5/2016Robert S RadieCEOSell5,000$4.94$24,700.00View SEC Filing  
7/5/2016Stan MusialCFOSell13,480$5.06$68,208.80View SEC Filing  
7/1/2016Robert S RadieCEOSell5,000$5.07$25,350.00View SEC Filing  
7/1/2016Stan MusialCFOSell10,000$5.06$50,600.00View SEC Filing  
6/30/2016Jeffrey M DaynoInsiderSell536$4.65$2,492.40View SEC Filing  
4/5/2016Deanne F MelloyInsiderSell860$6.96$5,985.60View SEC Filing  
4/5/2016Robert S RadieCEOSell5,000$6.99$34,950.00View SEC Filing  
4/4/2016Robert S RadieCEOSell10,000$6.97$69,700.00View SEC Filing  
1/11/2016Robert S. RadieCEOSell10,000$9.65$96,500.00View SEC Filing  
1/6/2016Robert S. RadieCEOSell5,000$10.52$52,600.00View SEC Filing  
10/6/2015Deanne F MelloyInsiderSell860$11.42$9,821.20View SEC Filing  
10/1/2015Robert S RadieCEOSell15,000$12.27$184,050.00View SEC Filing  
10/1/2015Stan MusialCFOSell8,480$12.32$104,473.60View SEC Filing  
9/30/2015Mark StrobeckInsiderSell5,220$12.56$65,563.20View SEC Filing  
7/8/2015Robert S RadieCEOSell6,000$11.97$71,820.00View SEC Filing  
7/6/2015Robert S RadieCEOSell9,000$12.53$112,770.00View SEC Filing  
7/1/2015Mark StrobeckInsiderSell10,440$12.98$135,511.20View SEC Filing  
7/1/2015Stan MusialCFOSell8,480$13.20$111,936.00View SEC Filing  
4/1/2015Robert S RadieCEOSell11,130$11.25$125,212.50View SEC Filing  
2/3/2015Jeffrey M DaynoInsiderSell2,500$8.87$22,175.00View SEC Filing  
1/2/2015Mark StrobeckInsiderSell3,480$5.09$17,713.20View SEC Filing  
1/2/2015Robert S RadieCEOSell11,130$5.11$56,874.30View SEC Filing  
9/10/2014Robert S RadieCEOSell40,040$9.61$384,784.40View SEC Filing  
9/8/2014Robert S RadieCEOSell49,000$9.74$477,260.00View SEC Filing  
8/13/2014Mark StrobeckInsiderSell5,135$9.20$47,242.00View SEC Filing  
8/11/2014Mark StrobeckInsiderSell5,700$10.28$58,596.00View SEC Filing  
8/7/2014Mark StrobeckInsiderSell3,085$11.50$35,477.50View SEC Filing  
8/7/2014Stan MusialCFOSell13,920$11.05$153,816.00View SEC Filing  
2/11/2014Jean Francois FormelaDirectorBuy41,667$12.00$500,004.00View SEC Filing  
2/11/2014Life Science Ventures SunstoneMajor ShareholderBuy133,333$12.00$1,599,996.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Egalet Corp (NASDAQ:EGLT)
Latest Headlines for Egalet Corp (NASDAQ:EGLT)
Source:
DateHeadline
finance.yahoo.com logoEgalet Announces Results of ARYMO® ER Harm Reduction Modeling Analysis
finance.yahoo.com - May 18 at 4:57 PM
seekingalpha.com logoEgalet publishes ARYMO ER data in journal of opioid management and American journal of drug and alcohol abuse
seekingalpha.com - May 17 at 11:01 AM
streetinsider.com logoEgalet (EGLT) Reports Publishing ARYMO ER Data & Top-Line Results from Study in Medical Journal
www.streetinsider.com - May 17 at 11:01 AM
finance.yahoo.com logoEgalet Announces ARYMO™ ER Data Published in Journal of Opioid Management and American Journal of Drug and Alcohol Abuse
finance.yahoo.com - May 17 at 11:01 AM
americanbankingnews.com logoFY2017 EPS Estimates for Egalet Corp (EGLT) Cut by Analyst
www.americanbankingnews.com - May 17 at 8:58 AM
finance.yahoo.com logoETFs with exposure to Egalet Corp. : May 15, 2017
finance.yahoo.com - May 15 at 4:02 PM
finance.yahoo.com logoEgalet Announces Scientific Presentations at American Pain Society Meeting
finance.yahoo.com - May 15 at 11:44 AM
finance.yahoo.com logoEgalet Corp. :EGLT-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 5:22 PM
americanbankingnews.com logoEgalet Corp (EGLT) Upgraded to Buy by Gabelli
www.americanbankingnews.com - May 12 at 9:20 AM
finance.yahoo.com logoPanel of Leading Pain Management Specialists Highlight Potential Role of Abuse-Deterrent Formulations of Opioids and Non-Narcotics to Help Curb Misuse and Abuse at Egalet Investor Day
finance.yahoo.com - May 11 at 5:33 PM
americanbankingnews.com logoEgalet Corp (EGLT) Posts Earnings Results
www.americanbankingnews.com - May 11 at 12:44 AM
americanbankingnews.com logoEgalet Corp (EGLT) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - May 10 at 11:54 PM
finance.yahoo.com logoEgalet Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 7:03 AM
marketbeat.com logoEgalet reports 1Q loss
marketbeat.com - May 10 at 6:24 AM
americanbankingnews.com logoEgalet Corp (EGLT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - May 9 at 7:30 PM
bizjournals.com logoResearch Reports Initiation on Biotech Stocks -- Egalet, Argos Therapeutics, Alder Biopharma, and Anavex Life Sciences
www.bizjournals.com - May 4 at 10:15 AM
americanbankingnews.com logoEgalet Corp (EGLT) Getting Very Positive Media Coverage, Analysis Finds
www.americanbankingnews.com - May 2 at 4:14 PM
americanbankingnews.com logoEgalet Corp (EGLT) Receiving Favorable News Coverage, Study Finds
www.americanbankingnews.com - April 27 at 10:30 AM
finance.yahoo.com logoEgalet to Report First Quarter 2017 Financial Results During Investor Day on May 10, 2017 in New York
finance.yahoo.com - April 26 at 11:39 PM
americanbankingnews.com logoEgalet Corp (EGLT) Earns Daily Media Impact Score of 0.39
www.americanbankingnews.com - April 19 at 11:31 AM
seekingalpha.com logoFDA accepts Egalet's PAS for OXAYDO 10/15 mg; shares ahead 9% premarket
seekingalpha.com - April 18 at 11:57 AM
finance.yahoo.com logoEgalet Announces U.S. Food and Drug Administration Acceptance of File for Prior Approval Supplement for OXAYDO® (oxycodone HCl, USP) tablets C-II 10 mg and 15 mg Dosage Strengths
finance.yahoo.com - April 18 at 11:57 AM
streetinsider.com logoEgalet (EGLT) Appoints Andrea Smiley to Board; Jean-Francois Formela Resigns
www.streetinsider.com - April 11 at 12:42 PM
finance.yahoo.com logoEgalet Corporation Announces Changes to Board of Directors
finance.yahoo.com - April 10 at 4:44 PM
americanbankingnews.com logoInsider Selling: Egalet Corp (EGLT) CFO Sells 8,613 Shares of Stock
www.americanbankingnews.com - April 5 at 9:16 PM
finance.yahoo.com logoEgalet to Participate in Spring Investor Conferences
finance.yahoo.com - April 4 at 6:43 AM
baystreet.ca logoEgalet (EGLT) Gains as FDA Challenge Still on Table
www.baystreet.ca - March 30 at 5:24 PM
finance.yahoo.com logoEgalet Deploys Salesforce to Begin Educating Healthcare Providers about ARYMO™ ER
finance.yahoo.com - March 30 at 5:24 PM
investopedia.com logoEgalet Can Tout Abuse-Deterrent Opioid Painkiller (EGLT)
www.investopedia.com - March 29 at 5:27 PM
investopedia.com logoEgalet Can Tout Abuse-Deterrent Opioid Painkiller
www.investopedia.com - March 29 at 5:27 PM
feeds.benzinga.com logoThe FDA News That Put The Wind Beneath Egalet Stock's Wings
feeds.benzinga.com - March 29 at 3:21 PM
us.rd.yahoo.com logoEgalet Announces U.S. Food and Drug Administration Does Not Object to Egalet's Distribution of Materials and Communications to Healthcare Professionals Regarding Abuse-Deterrent Properties of ARYMO™ ER via Intranasal Route
us.rd.yahoo.com - March 29 at 11:34 AM
biz.yahoo.com logoEGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 29 at 11:34 AM
finance.yahoo.com logoEgalet Corporation (Nasdaq: EGLT) to Ring The Nasdaq Stock Market Closing Bell
finance.yahoo.com - March 29 at 11:34 AM
finance.yahoo.com logoDEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders it Has Filed a Complaint to Recover Losses Suffered by Investors in Egalet Corporation, Sets Lead Plaintiff Deadline of March 28, 2017 - EGLT
finance.yahoo.com - March 28 at 12:02 PM
feeds.benzinga.com logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Egalet Corporation (EGLT) & Lead Plaintiff Deadline - March 28, 2017
feeds.benzinga.com - March 28 at 10:38 AM
americanbankingnews.com logoFY2017 EPS Estimates for Egalet Corp (EGLT) Reduced by Analyst
www.americanbankingnews.com - March 27 at 9:53 AM
finance.yahoo.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Egalet Corporation - EGLT
finance.yahoo.com - March 24 at 5:09 PM
investopedia.com logoEgalet Gets 4 Patents for Guardian Technology (EGLT)
www.investopedia.com - March 23 at 5:27 PM
finance.yahoo.com logoEgalet Announces Issuance of New U.S. and International Patents for Guardian™ Technology
finance.yahoo.com - March 23 at 5:27 PM
finance.yahoo.com logo6:03 am Egalet announces the issuance of new U.S. and international patents for its proprietary Guardian Technology
finance.yahoo.com - March 23 at 5:27 PM
investopedia.com logoEgalet Gets 4 New Patents for Guardian Technology
www.investopedia.com - March 23 at 5:27 PM
americanbankingnews.com logoCantor Fitzgerald Weighs in on Egalet Corp's FY2017 Earnings (EGLT)
www.americanbankingnews.com - March 23 at 9:47 AM
americanbankingnews.com logoEgalet Corp (EGLT) Insider Patrick M. Shea Sells 4,250 Shares
www.americanbankingnews.com - March 21 at 8:00 PM
finance.yahoo.com logoINVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Egalet Corporation and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - March 21 at 5:08 PM
investopedia.com logoNektar Opioid Drug Does Well In Study (NKTR, EGLT) - Investopedia
www.investopedia.com - March 21 at 8:22 AM
investopedia.com logoPain Therapeutics’ Remoxy ER Secures FDA Regulatory Guidance (PTIE,EGLT)
www.investopedia.com - March 21 at 8:22 AM
us.rd.yahoo.com logoSHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Egalet Corporation and Encourages Investors with Losses to Contact the Firm
us.rd.yahoo.com - March 20 at 7:41 PM
us.rd.yahoo.com logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Egalet Corporation (EGLT) and Lead Plaintiff Deadline - March 28, 2017
us.rd.yahoo.com - March 20 at 7:41 PM
capitalcube.com logoEgalet Corp. :EGLT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
us.rd.yahoo.com - March 20 at 7:41 PM

Social

Chart

Egalet Corp (EGLT) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff